{"event":"cancer-immunotherapy-tracker","title":"Cancer immunotherapy tracker: approvals and trial results","state":"developing","updated":"2026-10-10T00:00:00.000Z","entries":[{"id":"1tq9a1z","at":"2026-10-08T00:00:00.000Z","title":"FDA approves adjuvant atezolizumab plus chemotherapy in stage III dMMR colon cancer","status":"confirmed","cites":[{"id":"cancer-immunotherapy-atezolizumab-dmmr-colon-2026","n":2,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer","publisher":"US Food and Drug Administration","short":"US Food and Drug…"}]},{"id":"bho0ho","at":"2026-09-13T00:00:00.000Z","title":"Ivonescimab beats pembrolizumab on overall survival in HARMONi-2","status":"confirmed","cites":[{"id":"cancer-immunotherapy-harmoni-2-os","n":3,"url":"https://www.prnewswire.com/news-releases/ivonescimab-versus-pembrolizumab-in-first-line-pd-l1-positive-nsclc-positive-overall-survival-results-from-harmoni-2-presented-at-wclc-2026-302876953.html","publisher":"Akeso (press release via PR Newswire)","short":"Akeso"}]},{"id":"1ejutn3","at":"2026-09-01T00:00:00.000Z","title":"Blinatumomab replacing chemotherapy improves event-free survival in children with high-risk B-ALL (NEJM)","status":"confirmed","cites":[{"id":"cancer-immunotherapy-blinatumomab-pediatric-2026","n":16,"url":"https://doi.org/10.1056/NEJMoa2604166","publisher":"The New England Journal of Medicine","short":"The New England Journal…"}]},{"id":"1axlqeo","at":"2026-08-28T00:00:00.000Z","title":"BioNTech ends colorectal trial of autogene cevumeran after overall-survival imbalance","status":"confirmed","cites":[{"id":"cancer-immunotherapy-autogene-crc-terminated","n":8,"url":"https://www.biontech.com/int/en/home/mediaroom/news/statements/2026/08/BioNTech-Provides-Update-on-Phase-2-Clinical-Trial-of-Autogene-Cevumeran-in-Resected-Colorectal-Cancer.html","publisher":"BioNTech","short":"BioNTech"}]},{"id":"gyor3o","at":"2026-08-19T00:00:00.000Z","title":"Personalised mRNA therapy intismeran autogene meets phase 3 endpoints in melanoma","status":"confirmed","cites":[{"id":"cancer-immunotherapy-interpath-001","n":7,"url":"https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/","publisher":"Merck & Co.","short":"Merck & Co."}]},{"id":"lkqpi","at":"2026-08-06T00:00:00.000Z","title":"FDA grants accelerated approval to oncolytic virus vusolimogene oderparepvec with nivolumab in melanoma","status":"confirmed","cites":[{"id":"cancer-immunotherapy-vusolimogene-2026","n":25,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma","publisher":"US Food and Drug Administration","short":"US Food and Drug…"}]},{"id":"4snba2","at":"2026-06-24T00:00:00.000Z","title":"FDA approves sacituzumab govitecan with pembrolizumab in first-line triple-negative breast cancer","status":"confirmed","cites":[{"id":"cancer-immunotherapy-sacituzumab-pembro-2026","n":41,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line","publisher":"US Food and Drug Administration","short":"US Food and Drug…"}]},{"id":"vow65c","at":"2026-06-22T00:00:00.000Z","title":"China approves satri-cel, first CAR-T for a solid tumour","status":"confirmed","cites":[{"id":"cancer-immunotherapy-satri-cel-approval-date","n":11,"url":"https://www.biospace.com/press-releases/carsgen-announces-approval-of-satri-cel-the-worlds-first-car-t-cell-therapy-product-for-solid-tumors","publisher":"CARsgen Therapeutics (press release via BioSpace)","short":"CARsgen Therapeutics"},{"id":"cancer-immunotherapy-satri-cel-nmpa-2026","n":40,"url":"https://www.onclive.com/view/china-s-nmpa-approves-first-car-t-cell-therapy-for-cldn18--2-her2-advanced-gastric-gej-adenocarcinoma","publisher":"OncLive","short":"OncLive"}]},{"id":"1gbtj8p","at":"2026-06-02T00:00:00.000Z","title":"Kelonia reports MRD-negative responses in 18 patients with in vivo CAR-T KLN-1010 at ASCO","status":"reported","cites":[{"id":"cancer-immunotherapy-kln-1010","n":24,"url":"https://ascopost.com/issues/february-25-2026-supplement-ash-meeting-highlights-2025/early-findings-from-first-human-study-of-in-vivo-car-t-in-myeloma/","publisher":"The ASCO Post","short":"The ASCO Post"}]},{"id":"1bkw6ry","at":"2026-05-31T00:00:00.000Z","title":"Ivonescimab beats tislelizumab-chemotherapy on overall survival in HARMONi-6","status":"confirmed","cites":[{"id":"cancer-immunotherapy-harmoni-6-os","n":9,"url":"https://www.prnewswire.com/news-releases/harmoni-6-demonstrates-significant-overall-survival-benefit-hr0-66-ivonescimab-plus-chemotherapy-superior-to-pd-1-plus-chemotherapy-in-first-line-sq-nsclc-landmark-results-to-be-presented-at-asco-2026-plenary-session-302786433.html","publisher":"Akeso (press release via PR Newswire)","short":"Akeso"}]},{"id":"12hr7lz","at":"2026-04-01T00:00:00.000Z","title":"Phase 1 report of in vivo CAR-T ESO-T01 in myeloma published in Nature Medicine","status":"confirmed","body":"Four of five patients responded; all had grade 3 or higher adverse events and one died.","cites":[{"id":"cancer-immunotherapy-eso-t01-results","n":39,"url":"https://doi.org/10.1038/s41591-026-04244-6","publisher":"Nature Medicine","short":"Nature Medicine"},{"id":"cancer-immunotherapy-eso-t01-safety","n":12,"url":"https://doi.org/10.1038/s41591-026-04244-6","publisher":"Nature Medicine","short":"Nature Medicine"}]},{"id":"kjrw02","at":"2026-03-18T00:00:00.000Z","title":"In vivo CRISPR insertion of a CAR gene generates CAR-T cells in mice (Nature)","status":"confirmed","cites":[{"id":"cancer-immunotherapy-in-vivo-crispr-car","n":13,"url":"https://doi.org/10.1038/s41586-026-10235-x","publisher":"Nature","short":"Nature"}]},{"id":"74urqk","at":"2026-03-05T00:00:00.000Z","title":"FDA approves teclistamab plus daratumumab in earlier-line myeloma","status":"confirmed","cites":[{"id":"cancer-immunotherapy-teclistamab-2026","n":38,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-combination-daratumumab-hyaluronidase-fihj-relapsed-or-refractory-multiple","publisher":"US Food and Drug Administration","short":"US Food and Drug…"}]},{"id":"p02zvh","at":"2026-02-18T00:00:00.000Z","title":"Individualised mRNA vaccine shows durable T-cell responses in triple-negative breast cancer (Nature, single arm)","status":"confirmed","cites":[{"id":"cancer-immunotherapy-tnbc-mrna-vaccine","n":29,"url":"https://doi.org/10.1038/s41586-025-10004-2","publisher":"Nature","short":"Nature"}]},{"id":"5lhbgt","at":"2026-01-29T00:00:00.000Z","title":"FDA accepts ivonescimab application with 14 November 2026 goal date","status":"confirmed","cites":[{"id":"cancer-immunotherapy-ivonescimab-bla","n":22,"url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000006/a2026_prx0129xfdablaacce.htm","publisher":"Summit Therapeutics (SEC filing)","short":"Summit Therapeutics"}]},{"id":"1aojp6e","at":"2026-01-16T00:00:00.000Z","title":"Shared-neoantigen vaccine Nous-209 induces immune responses in Lynch syndrome carriers (Nature Medicine)","status":"confirmed","cites":[{"id":"cancer-immunotherapy-nous-209","n":28,"url":"https://doi.org/10.1038/s41591-025-04182-9","publisher":"Nature Medicine","short":"Nature Medicine"}]},{"id":"1nn1lqw","at":"2025-12-09T00:00:00.000Z","title":"MajesTEC-3 teclistamab-daratumumab results published in NEJM","status":"confirmed","cites":[{"id":"cancer-immunotherapy-majestec-3-detail","n":20,"url":"https://doi.org/10.1056/NEJMoa2514663","publisher":"The New England Journal of Medicine","short":"The New England Journal…"}]},{"id":"ybd0fr","at":"2025-12-04T00:00:00.000Z","title":"FDA approves first CAR-T therapy for marginal zone lymphoma","status":"confirmed","cites":[{"id":"cancer-immunotherapy-breyanzi-mzl-2025","n":37,"url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-car-t-cell-therapy-marginal-zone-lymphoma-us","publisher":"US Food and Drug Administration","short":"US Food and Drug…"}]},{"id":"1rjk4dc","at":"2025-09-19T00:00:00.000Z","title":"FDA approves subcutaneous pembrolizumab (Keytruda Qlex)","status":"confirmed","cites":[{"id":"cancer-immunotherapy-keytruda-qlex-2025","n":15,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection","publisher":"U.S. Food and Drug Administration","short":"U.S. Food and Drug…"}]},{"id":"1nn024s","at":"2025-07-24T00:00:00.000Z","title":"Tarlatamab improves overall survival in phase 3 DeLLphi-304 (NEJM)","status":"confirmed","cites":[{"id":"cancer-immunotherapy-dellphi-304","n":36,"url":"https://doi.org/10.1056/NEJMoa2502099","publisher":"New England Journal of Medicine","short":"New England Journal…"}]},{"id":"1bp73h4","at":"2025-06-26T00:00:00.000Z","title":"FDA eliminates REMS requirements for autologous CAR-T therapies","status":"confirmed","cites":[{"id":"cancer-immunotherapy-rems-fda-2025","n":26,"url":"https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor","publisher":"U.S. Food and Drug Administration","short":"U.S. Food and Drug…"},{"id":"cancer-immunotherapy-car-t-rems-2025","n":35,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12523345/","publisher":"Cancers (MDPI)","short":"Cancers"}]},{"id":"130g0gi","at":"2025-06-01T00:00:00.000Z","title":"Randomised trial of claudin-18.2 CAR-T satri-cel in gastric cancer published in The Lancet","status":"confirmed","cites":[{"id":"cancer-immunotherapy-satri-cel-lancet-2025","n":34,"url":"https://doi.org/10.1016/S0140-6736(25)00860-8","publisher":"The Lancet","short":"The Lancet"}]},{"id":"zp77g3","at":"2024-08-02T00:00:00.000Z","title":"FDA approves Tecelra, the first engineered T-cell receptor therapy, in synovial sarcoma","status":"confirmed","cites":[{"id":"cancer-immunotherapy-tecelra-2024","n":10,"url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma","publisher":"U.S. Food and Drug Administration","short":"U.S. Food and Drug…"}]},{"id":"13coa6o","at":"2024-06-02T00:00:00.000Z","title":"NADINA shows neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma (NEJM)","status":"confirmed","cites":[{"id":"cancer-immunotherapy-nadina","n":14,"url":"https://doi.org/10.1056/NEJMoa2402604","publisher":"The New England Journal of Medicine","short":"The New England Journal…"}]},{"id":"1bpamrh","at":"2024-05-16T00:00:00.000Z","title":"FDA grants accelerated approval to tarlatamab, a DLL3 x CD3 T-cell engager, in small cell lung cancer","status":"confirmed","cites":[{"id":"cancer-immunotherapy-tarlatamab-2024","n":33,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer","publisher":"US Food and Drug Administration","short":"US Food and Drug…"}]},{"id":"qlodhq","at":"2024-04-18T00:00:00.000Z","title":"FDA requires boxed warning for T-cell malignancies on CAR-T products","status":"confirmed","cites":[{"id":"cancer-immunotherapy-car-t-boxed-warning-2024","n":32,"url":"https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed","publisher":"US Food and Drug Administration","short":"US Food and Drug…"}]},{"id":"s9fo13","at":"2024-02-16T00:00:00.000Z","title":"FDA approves lifileucel, the first tumour-derived T-cell therapy, for advanced melanoma","status":"confirmed","cites":[{"id":"cancer-immunotherapy-lifileucel-2024","n":31,"url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma","publisher":"US Food and Drug Administration","short":"US Food and Drug…"}]},{"id":"nwke5j","at":"2024-02-01T00:00:00.000Z","title":"KEYNOTE-942 phase 2b results for mRNA-4157 plus pembrolizumab published in The Lancet","status":"confirmed","cites":[{"id":"cancer-immunotherapy-keynote-942","n":30,"url":"https://doi.org/10.1016/S0140-6736(23)02268-7","publisher":"The Lancet","short":"The Lancet"}]},{"id":"1mii7m7","at":"2023-12-15T00:00:00.000Z","title":"FDA approves enfortumab vedotin plus pembrolizumab in advanced urothelial cancer (EV-302)","status":"confirmed","cites":[{"id":"cancer-immunotherapy-ev-302-approval","n":27,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer","publisher":"U.S. Food and Drug Administration","short":"U.S. Food and Drug…"},{"id":"cancer-immunotherapy-ev-302","n":19,"url":"https://doi.org/10.1056/NEJMoa2312117","publisher":"The New England Journal of Medicine","short":"The New England Journal…"}]},{"id":"as2wha","at":"2018-10-01T00:00:00.000Z","title":"Allison and Honjo win the Nobel Prize for checkpoint-blockade cancer therapy","status":"confirmed","cites":[{"id":"cancer-immunotherapy-nobel-2018","n":6,"url":"https://www.nobelprize.org/prizes/medicine/2018/press-release/","publisher":"Nobel Assembly at Karolinska Institutet (NobelPrize.org)","short":"Nobel Assembly at…"}]},{"id":"1eeljlb","at":"2011-03-25T00:00:00.000Z","title":"FDA approves ipilimumab (Yervoy), the first immune checkpoint inhibitor, for advanced melanoma","status":"confirmed","cites":[{"id":"cancer-immunotherapy-ipilimumab-approval-date","n":5,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377","publisher":"U.S. Food and Drug Administration (Drugs@FDA)","short":"U.S. Food and Drug…"},{"id":"cancer-immunotherapy-ipilimumab-2011","n":4,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4530113/","publisher":"Journal of the Advanced Practitioner in Oncology","short":"Journal of the Advanced…"}]}]}